Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis’ proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs, with a focus in oncology. This represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer.

How many organisations/clients currently utilise the service/solution across the UK?
End of December 2019, Biocartis had an installed base of over 1,300 Idylla™’s of which the majority in European countries and the UK

Is there anything you would like to make delegates aware of ahead of the Sepsis+ Managing Deteriorating Conditions conference on 11th February?
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis’ proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs. Together with Immunexpress Pty Ltd (‘Immunexpress’), a Seattle-based molecular diagnostic company, Biocartis launched the SeptiCyte® RAPID Test (CE-IVD) for use on Biocartis’ fully automated molecular diagnostics platform Idylla™. The SeptiCyte® RAPID Test is a rapid, host-response test that distinguishes sepsis from infection negative systemic inflammation in patients suspected of sepsis and provides actionable results in around one hour to guide the physician to optimize patient management decisions. Recent data indicate that sepsis is the most frequently observed complication in COVID-19 . In current COVID-19 pandemic times, hospitals and ICU’s are under enormous pressure and SeptiCyte® RAPID could be a great support in detecting sepsis early on and supporting decisions for rapid initiation of sepsis management protocols in affected patients. Immunexpress expects US FDA 510(k) clearance of the SeptiCyte® RAPID Test by the third quarter of 2020.

What do you feel are the key points delegates need to digest when considering a partnership with your organisation?
Partnerships are a cornerstone for Biocartis’ in expanding its test menu on the Idylla™ platform. Today, Biocartis has partnerships in place in the field of oncology and infectious diseases with: A*STAR, Amgen, AstraZeneca, Bristol Myers Squibb, Covance, Exact Sciences, Immunexpress, Kite, LifeArc, Merck KGaA, Nichirei Biosciences and Wondfo. More info on https://www.biocartis.com/en/about-us/our-partners

Contact Information:

Address:
Generaal de Wittelaan
11 B3 – 2800
Mechelen
Belgium

Tel:           3215600632
Email:      info@biocartis.com

Latest Posts
Event Search

You should choose a search result page. You can choose the page from the Theme Options > Events > Event Search Results Page option.

Ads
Latest Events